[Skip to Content]
[Skip to Content Landing]
December 16, 1988

Immunoaugmentative Therapy-Reply

Author Affiliations

American Medical Association Chicago

American Medical Association Chicago

JAMA. 1988;260(23):3436-3437. doi:10.1001/jama.1988.03410230053021

In Reply.—  In his editorial, Dr Nightingale1 did not indicate awareness that every DATTA survey packet includes standard definitions for established, investigational, unacceptable, indeterminate, safety, and effectiveness. These definitions are now published with every DATTA opinion.2Dr Nightingale and Mr Wiewel question applying the standard DATTA process to IAT. The DATTA surveys provide qualitative evaluations based on the opinions of a large number of experts and review of the scientific literature. In that context, the study of IAT was appropriate. Patients and physicians are making decisions about IAT now and they need the best information available, even if it is incomplete. We are actively pursuing enhancements to DATTA and appreciate Dr Nightingale's comments.Nevertheless, while published peerreviewed data directly supporting any efficacy for IAT in humans do not exist, there are data on the safety of IAT. The DATTA panel was aware of these data and based